PL1748770T3 - Leczenie i zapobieganie dobrotliwej chorobie sutka 4-hydroksytamoksyfenem - Google Patents

Leczenie i zapobieganie dobrotliwej chorobie sutka 4-hydroksytamoksyfenem

Info

Publication number
PL1748770T3
PL1748770T3 PL05716433T PL05716433T PL1748770T3 PL 1748770 T3 PL1748770 T3 PL 1748770T3 PL 05716433 T PL05716433 T PL 05716433T PL 05716433 T PL05716433 T PL 05716433T PL 1748770 T3 PL1748770 T3 PL 1748770T3
Authority
PL
Poland
Prior art keywords
benign breast
hydroxy tamoxifen
breast disease
prevention
treatment
Prior art date
Application number
PL05716433T
Other languages
English (en)
Inventor
Nestour Elisabeth Le
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/805,528 external-priority patent/US7507769B2/en
Priority claimed from EP04290761A external-priority patent/EP1579856A1/en
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of PL1748770T3 publication Critical patent/PL1748770T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05716433T 2004-03-22 2005-03-10 Leczenie i zapobieganie dobrotliwej chorobie sutka 4-hydroksytamoksyfenem PL1748770T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/805,528 US7507769B2 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP04290761A EP1579856A1 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP05716433A EP1748770B1 (en) 2004-03-22 2005-03-10 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
PCT/EP2005/003286 WO2005092309A1 (en) 2004-03-22 2005-03-10 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
PL1748770T3 true PL1748770T3 (pl) 2008-09-30

Family

ID=34961912

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05716433T PL1748770T3 (pl) 2004-03-22 2005-03-10 Leczenie i zapobieganie dobrotliwej chorobie sutka 4-hydroksytamoksyfenem

Country Status (16)

Country Link
EP (1) EP1748770B1 (pl)
JP (1) JP5072588B2 (pl)
CN (1) CN1946387B (pl)
AT (1) ATE391499T1 (pl)
AU (1) AU2005227072B2 (pl)
CA (1) CA2559748C (pl)
DE (1) DE602005005986T2 (pl)
DK (1) DK1748770T3 (pl)
ES (1) ES2306111T3 (pl)
MX (1) MXPA06010914A (pl)
NO (1) NO336767B1 (pl)
NZ (1) NZ549817A (pl)
PL (1) PL1748770T3 (pl)
PT (1) PT1748770E (pl)
RU (1) RU2357726C2 (pl)
WO (1) WO2005092309A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1799201T3 (da) * 2004-10-14 2009-03-30 Besins Int Lab 4-Hydroxy-tamoxifen gelformuleringer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ES2044860T3 (es) * 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
CN1320880C (zh) * 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
DK1317921T3 (da) * 2001-12-07 2009-12-21 Besins Mfg Belgium Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
EP1952809B1 (en) * 2002-12-18 2017-08-02 Besins Healthcare Luxembourg SARL Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen
ES2483896T3 (es) * 2003-04-01 2014-08-08 Besins Healthcare Luxembourg Sarl Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
JP5069469B2 (ja) * 2003-12-15 2012-11-07 ラボラトワール ブザン アンテルナスィヨナル 女性化乳房治療用の薬剤を製造する際の4−ヒドロキシタモキシフェンの使用

Also Published As

Publication number Publication date
WO2005092309A1 (en) 2005-10-06
DE602005005986D1 (de) 2008-05-21
NO336767B1 (no) 2015-10-26
DK1748770T3 (da) 2008-08-04
JP2007535505A (ja) 2007-12-06
ES2306111T3 (es) 2008-11-01
RU2006137280A (ru) 2008-04-27
NO20064609L (no) 2006-10-11
AU2005227072A1 (en) 2005-10-06
CN1946387B (zh) 2011-08-31
MXPA06010914A (es) 2006-12-15
EP1748770B1 (en) 2008-04-09
EP1748770A1 (en) 2007-02-07
AU2005227072B2 (en) 2010-08-19
CA2559748A1 (en) 2005-10-06
ATE391499T1 (de) 2008-04-15
CA2559748C (en) 2013-05-28
JP5072588B2 (ja) 2012-11-14
DE602005005986T2 (de) 2009-06-04
HK1096595A1 (en) 2007-06-08
RU2357726C2 (ru) 2009-06-10
NZ549817A (en) 2010-06-25
PT1748770E (pt) 2008-07-16
CN1946387A (zh) 2007-04-11

Similar Documents

Publication Publication Date Title
MXPA05010597A (es) Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
SE0300098D0 (sv) Use of cyclin D1 inhibitors
EA201270298A1 (ru) Способ лечения злокачественной опухоли
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
PT1748770E (pt) Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
AR025718A1 (es) Metodo para reducir el riesgo de cancer
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
MD2849G2 (ro) Metodă de tratament al cancerului mamar la pacientele de vârstă înaintată
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
RU2008107113A (ru) Средство и способ профилактики и лечения пациентов с болезнью альцгеймера
RU2004116477A (ru) Применение n, n-диэтил-2-[4-(фенилметил)фенокси]этанамина моногидрохлорида (dppe) при лечении раковых заболеваний
CN208113994U (zh) 一种纯银排毒消炎女性内衣
Kalra et al. Brisk Erythematous Reaction Outside of the Radiation Field in a Patient Treated With Adjuvant Radiation for Phyllodes Tumor
CN204812059U (zh) 一种防辐射内裤
Parsons et al. Examining the time-to-improvement of sleep disturbance in patients with painful diabetic peripheral neuropathy and post-herpetic neuralgia
Temelkova et al. Lipoma of the Neck. Open Access Maced J Med Sci. 2018 Oct 25; 6 (10): 1875-1877
García-Fernández et al. Predictive value of optical coherence tomography on the outcome of lung adenocarcinoma with choroidal metastases
Stehr et al. A Clinical Perspective of Bilateral Renal Tumors-Data from Three Consecutive German Cooperative Trials
Kim et al. Granular Cell Tumor in the Sartorius Muscle